Bolt Biotherapeutics (NASDAQ:BOLT) Releases Quarterly Earnings Results, Beats Expectations By $1.43 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) posted its quarterly earnings data on Thursday. The company reported ($2.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.68) by $1.43, FiscalAI reports. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%.

Bolt Biotherapeutics Price Performance

Shares of BOLT traded down $0.35 during mid-day trading on Thursday, hitting $5.91. The company’s stock had a trading volume of 177,672 shares, compared to its average volume of 92,765. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 1.47. Bolt Biotherapeutics has a 1-year low of $3.10 and a 1-year high of $7.78. The firm has a market capitalization of $11.41 million, a P/E ratio of -0.36 and a beta of 0.85. The firm has a 50-day simple moving average of $4.54 and a 200 day simple moving average of $4.52.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and a consensus price target of $14.50.

Insiders Place Their Bets

In other Bolt Biotherapeutics news, CEO William P. Quinn sold 9,132 shares of the business’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $3.24, for a total transaction of $29,587.68. Following the sale, the chief executive officer directly owned 25,384 shares in the company, valued at approximately $82,244.16. The trade was a 26.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Coastlands Capital Lp purchased 50,000 shares of the stock in a transaction dated Monday, November 9th. The shares were bought at an average cost of $6.38 per share, for a total transaction of $319,000.00. Following the completion of the purchase, the insider owned 462,416 shares in the company, valued at approximately $2,950,214.08. This trade represents a 12.12% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold 38,584 shares of company stock worth $128,361 in the last ninety days. 9.40% of the stock is currently owned by corporate insiders.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.